Brain Cancer News and Research

RSS

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Innovative hands-free device can reduce risk of cancer from cell phone radiation

A new report from the World Health Organization (WHO)/Interactional Agency for Research on Cancer (IARC) released last week has revealed another potential health risk for consumers.

9 Jun 2011

IsoRay completes Iotrex license agreement with Dr. Reddy's

IsoRay, Inc. announced today that it has completed a license agreement with Dr. Reddy's Laboratories for exclusive worldwide licensing rights to Iotrex, a liquid iodine radiation, for use in brain cancer treatment.

7 Jun 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

4 Jun 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant, according to an abstract being presented at the American Society of Clinical Oncology annual meeting in Chicago by Thomas Jefferson University Hospital researchers on Saturday, June 4.

4 Jun 2011

Maryland researchers deny link between cell phone radiation and brain cancer

University of Maryland researchers in the A. James Clark School of Engineering have expressed concerns regarding the validity of recent findings announced in the Journal of the American Medical Association and a World Health Organization panel suggesting that radiation from cell phones may be carcinogenic.

4 Jun 2011

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

Brain cancer therapy may be more effective if the expression of an iron-storing protein is decreased to enhance the action of therapeutic drugs on brain cancer cells, according to Penn State College of Medicine researchers.

4 Jun 2011

WHO/IARC say mobile phone use may increase risk of certain brain cancers

Mobile phone use "may increase the risk of certain types of brain cancer in humans," therefore "consumers should consider ways of reducing their exposure," a WHO/International Agency for Research on Cancer (IARC) working group concluded on Tuesday, Reuters reports.

2 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Cell phones and cancer – link established

In its latest announcement the World Health Organization (WHO) said that radiation from cell phones can possibly cause cancer. According to the WHO's International Agency for Research on Cancer (IARC), radiofrequency electromagnetic fields have been classified as possibly carcinogenic to humans (group 2B) on the basis of an increased risk for glioma that some studies have associated with the use of wireless phones.

1 Jun 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

In collaboration with the International EMF Alliance (IEMFA), scientists from Europe, North America, Australia and Israel have sent an Open Letter to Dr. Christopher Wild, Director of the International Agency for Research on Cancer (IARC), calling for a postponement of the forthcoming meeting May 24-31, 2011 in Lyon, France, “Non-Ionizing Radiation, Part II: Radiofrequency Electromagnetic Field [includes mobile telephones],” at which determination of the carcinogenicity of cell phones and wireless technologies will be made.

22 May 2011

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

Although chemotherapy is used to kill cancer cells, it can also have a strong toxic effect on normal cells such as bone marrow and blood cells, often limiting the ability to use and manage the chemotherapy treatment.

21 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.

17 May 2011

IsoRay third fiscal quarter sales increase 17%

IsoRay Inc., announced financial results for the third fiscal quarter ended March 31, 2011 underscoring significant improvements in quarterly sales revenue growth both sequentially and in the prior year quarter. Sales increased 17% in the period with the Company posting a 581% gain in gross profit compared to the prior year third quarter.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Brain Cancer News and Research

Further Reading

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Innovative hands-free device can reduce risk of cancer from cell phone radiation

IsoRay completes Iotrex license agreement with Dr. Reddy's

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Survival rates of wealthier patients with glioblastoma are longer than poorer patients

Maryland researchers deny link between cell phone radiation and brain cancer

Decreasing iron-storing protein expression can enhance action of brain cancer therapy: Researchers

WHO/IARC say mobile phone use may increase risk of certain brain cancers

New genetic test can predict clinical outcomes in glioblastoma patients

Cell phones and cancer – link established

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Global scientists rebuke coming decision on carcinogenicity of radiofrequency and microwaves

Modified cells protect marrow and blood cells from harmful chemotherapy effects in brain tumor patients

MDxHealth reduces first quarter net loss by 17%

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

CytRx sells global rights of molecular chaperone assets to Orphazyme

IsoRay third fiscal quarter sales increase 17%

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News